Your Watch Will One Day Track Blood Pressure

Why It Matters

Cuff‑less, continuous blood‑pressure monitoring can become a standard smartwatch feature, expanding personal health data and reducing disparities. This breakthrough opens a new market segment for wearable health technology.

Key Takeaways

• Near‑field RF reflections map systolic/diastolic pressure
• Prototype uses only 3.4 mW power
• No skin contact removes tone‑bias
• Future versions add 5 GHz and 915 MHz
• Smartwatch integration targeted in next few years

Pulse Analysis

The quest for cuff‑less blood‑pressure monitoring has accelerated as consumers demand health insights without interrupting daily life. Traditional sphygmomanometers provide accurate snapshots but cannot deliver continuous data, prompting researchers to explore ultrasound patches, photoplethysmography, and bio‑impedance sensors. While these approaches have shown promise, they often require prolonged skin contact, suffer from motion artefacts, or exhibit bias linked to skin pigmentation. Consequently, wearable manufacturers have struggled to embed reliable, unbiased BP tracking into smartwatches, leaving a gap between consumer expectations and clinical‑grade measurement.

The University of Texas at Austin team tackled this gap by exploiting near‑field radio‑frequency reflections from the wrist. During each cardiac cycle, changes in tissue conductivity and dielectric properties alter the phase and amplitude of a 2.4 GHz microwave signal reflected by a patch antenna. By routing the signal through a circulator and a custom low‑power integrated circuit, the system captures these subtle variations with just 3.4 mW consumption. Laboratory tests using a vector network analyzer demonstrated clear differentiation between systolic and diastolic phases, all without any skin‑contact or reliance on optical measurements, thereby sidestepping tone‑bias concerns.

If the prototype scales to a smartwatch form factor, it could redefine the wearable health market. Continuous, non‑invasive BP data would empower users to detect hypertension trends early, support remote patient monitoring, and provide insurers with richer risk metrics. However, commercial rollout will hinge on meeting FDA accuracy standards, ensuring robust performance across diverse body types, and integrating multi‑frequency operation to accommodate varying tissue characteristics. Success would not only open new revenue streams for device makers but also democratize cardiovascular monitoring, reducing disparities that have plagued existing optical sensors.